Evidence map›Paper›PMID 33922315›Full record

ArticleCells2021

Metabolic Signatures in Coronary Artery Disease: Results from the BioHEART-CT Study.

Stephen T Vernon, Owen Tang, Taiyun Kim, Adam S Chan, Katharine A Kott, John Park, Thomas Hansen, Yen C Koay, Stuart M Grieve, John F O'Sullivan and 2 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Stephen T VernonCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.
Owen TangCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.
Taiyun KimCharles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-5028-836X
Adam S ChanCharles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.
Katharine A KottCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.ORCID 0000-0001-9923-2722
John ParkCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.
Thomas HansenCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.
Yen C KoayCharles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.
Stuart M GrieveImaging and Phenotyping Laboratory, Charles Perkins Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-2712-157X
John F O'SullivanCharles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.
Jean Y YangCharles Perkins Centre, University of Sydney, Sydney, NSW 2006, Australia.
Gemma A FigtreeCardiothoracic and Vascular Health, Kolling Institute, Northern Sydney Local Health District, Sydney, NSW 2065, Australia.
The University of Sydney · AUNorthern Sydney Local Health District · AU

Funding

BioPlatforms Australia N/AHeart Research Australia N/ARamsay Teaching and Research Foundation N/AVonwiller Foundation N/A
6 · The paper itself

Abstract

Despite effective prevention programs targeting cardiovascular risk factors, coronary artery disease (CAD) remains the leading cause of death. Novel biomarkers are needed for improved risk stratification and primary prevention. To assess for independent associations between plasma metabolites and specific CAD plaque phenotypes we performed liquid chromatography mass-spectrometry on plasma from 1002 patients in the BioHEART-CT study. Four metabolites were examined as candidate biomarkers. Dimethylguanidino valerate (DMGV) was associated with presence and amount of CAD (OR) 1.41 (95% Confidence Interval [CI] 1.12-1.79,

Indexed as

MetabolomeAgedBiomarkersCoronary Artery DiseaseFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedPlaque, AtheroscleroticPrognosisProspective StudiesRisk AssessmentRisk FactorsBiomarkersatherosclerosiscoronary artery diseasemetabolitesmetabolomicsrisk factors

Identifiers

PMID33922315
PMCPMC8145337
OpenAlexW3152959557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.